MNMD (MindMed) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of mindmed.co (MNMD)

Mind Medicine (MNMD) is accelerating drug discovery by leveraging AI and robotics to automate bioscreening. The current EV/EBITDA valuation reflects a market balance where 0.00 shapes the current metric. The potential to monopolize the psychedelics niche could enable high therapy pricing power. Meanwhile, management is currently optimizing the clinical plan, seeking to attract investment without share dilution.

MNMD (Mind Medicine (MindMed) Inc.) Company Value to EBITDA history from 11/23/2025 to 01/15/2026

Comprehensive metric breakdowns and analytics for mindmed.co (MNMD)

- market price and analyst price targets:
Price Chart MindMed Inc.|MNMD - Forecast Levels Chart
- business market valuation indicators:
Market Value Mind Medicine Corp|MNMD - Company Buyout Price
- book value of equity indicators:
Accounting Value per Share MindMed|MNMD - Total Stockholders' Equity|Market Capitalization to Book Value Ratio mindmed.co|MNMD - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Mind Medicine|MNMD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity MindMed|MNMD - Company Cumulative Debt|Debt to Book Capitalization Ratio Mind Medicine Corp|MNMD - Company Long-Term Liabilities|Company Short-Term Debts MindMed|Quick Liquidity mindmed.co
- net income and valuation multiples indicators:
MNMD - Company Profit|Projected Future Earnings Mind Medicine|MNMD - Price to Earnings Multiple|Projected Price to Earnings Mind Medicine|MNMD - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mind Medicine Corp|MNMD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) MindMed|MNMD - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth mindmed.co|MNMD - Earnings per share growth this year|Earnings growth forecast for next year Mind Medicine
Initial company analysis:MNMD (MindMed Inc.)
Product sample of MindMed

For Mind Medicine (MNMD), operating in the high-risk psychedelic psychiatry sector, this indicator is critical for assessing capitalization resilience in the face of regulatory barriers and R&D costs. By analyzing the Enterprise Value to EBITDA multiple, an investor can see the ratio of market weight and debt to actual cash flow, which helps identify asset overvaluation amid the uncertainty of clinical trials.

Competitors of Mind Medicine (MNMD)

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc. ALKS|AVDL (Avadel Corp) - Company Value to Operating Income Before Depreciation Ratio|ATAI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ghres.com GHRS|CMPS (COMPASS Pathways) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA LB Pharmaceuticals, Inc. (LBRX)|DRUG (Bright Minds Biosciences Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Vanda (VNDA)|EV/EBITDA Multiple CYBN|ANRO (altoneuroscience.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NRx Pharmaceuticals, Inc. NRXP|Cingulate Inc (CING) - Company Value to EBITDA|SILO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|China Pharma Holdings (CPHI) - Enterprise Value to EBITDA Ratio|CMND: EV/EBITDA Multiple|PBM - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SciSparc|Enterprise Value to Operating Income Before Depreciation SEEL (Seelos Therapeutics Inc.)|EV/EBITDA Multiple VRPX|Karuna Pharma - Enterprise Value to Operating Income Before Depreciation